Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

3 1 1 1

What is this study about?

This clinical trial is focused on studying the prevention of venous thromboembolism (VTE), a condition where blood clots form in the veins, in patients undergoing total hip or knee replacement surgery. The study will compare different approaches to preventing these clots, including a personalized method versus the standard approach. The trial aims to determine the effectiveness and safety of these methods in patients with varying levels of risk for developing VTE.

The trial will involve several medications, including Enoxaparin Sodium, Dabigatran, Nadroparin Calcium, Apixaban, Dalteparin Sodium, Rivaroxaban, Andexanet Alfa, and a combination product containing Human Coagulation Factors. These medications are known as anticoagulants, which help prevent blood clots. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs.

Participants in the study will be monitored for three months after their surgery to track the occurrence of VTE and any major bleeding events. The study will also look at other health outcomes, such as heart attacks, strokes, and infections related to the joint replacement. The goal is to find the best way to prevent blood clots while ensuring patient safety during and after surgery.

1 joining the study

Upon joining the study, participation begins with an initial assessment to confirm eligibility. This includes verifying that the individual is scheduled for an elective total hip or knee replacement and is 18 years or older.

2 randomization

Participants are randomly assigned to one of the study groups. Each group receives a different approach to prevent blood clots, known as venous thromboembolism (VTE), after surgery.

3 medication administration

Depending on the assigned group, participants receive specific medications to prevent VTE. These medications include enoxaparin sodium and nadroparin calcium administered via subcutaneous injection, and apixaban and rivaroxaban taken orally.

In some cases, andexanet alfa or a combination of human coagulation factors may be administered through infusion.

4 hospital stay

During the hospital stay, participants receive thrombosis prophylaxis as per their assigned group. The effectiveness of in-hospital thrombosis prophylaxis is evaluated, especially for those with low VTE risk.

5 postoperative period

For the first three months after surgery, the number of VTE events and major bleeding incidents are monitored. Participants may receive intensified thrombosis prophylaxis if they are at high risk for VTE.

6 follow-up assessments

Regular follow-up assessments are conducted to monitor for any clinically relevant non-major bleeding, prosthetic joint infections, and other health outcomes such as heart attack, stroke, or death.

The impact of these events on quality of life and healthcare costs is also evaluated.

Who Can Join the Study?

Patients must be scheduled to have a planned surgery for a Total Hip Replacement or Total Knee Replacement. These are surgeries to replace a hip or knee joint with an artificial one.
Patients must be 18 years old or older.
Both men and women can participate.
Patients should not be part of a vulnerable population, meaning they should not be in a group that needs special protection or care.

Who Cannot Join the Study?

Patients who have a history of venous thromboembolism (VTE), which is a condition where blood clots form in the veins.
Patients who are not within the specified age range for the study.
Patients who are not part of the specified clinical trial group.
Patients who are considered part of a vulnerable population, meaning they may have additional health or social factors that require special consideration.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Zuyderland Medisch Centrum Stichting	Geleen	The Netherlands
Stichting OLVG	Amsterdam	The Netherlands

Other Sites

Site Name	City	Country
Isala Klinieken Stichting	Zwolle	The Netherlands
Groene Hart Ziekenhuis	Gouda	The Netherlands
ZorgSaam Ziekenhuis	Terneuzen	The Netherlands
Alrijne Zorggroep Stichting	Leiderdorp	The Netherlands
St. Antonius Ziekenhuis	Nieuwegein	The Netherlands
Bravis Ziekenhuis	Roosendaal	The Netherlands
Gelre Hospitals	Zutphen	The Netherlands
Lctvo Ucpwkeqrxoib Mbrwjor Ciryzed (uhwrz	Leiden	The Netherlands
Bxomaeq Cqfxbab Nhhousfwo Birq	Naarden	The Netherlands
Ejpqlu Zysvfsgfmnfni Nbeenrrzw Btxw	Eindhoven	The Netherlands
Rafqidj Hhjd Gjyfx Omfirfspessc Cuomymc Bkkp	Zoetermeer	The Netherlands
Ssshxlw	Geldrop	The Netherlands
Som Ewxnmvwjn Hbpjdtfk Tmtfamq	Tilburg	The Netherlands

Trial status

Country	Status	Recruitment Start
The Netherlands	Recruiting	01.09.2024

Trial locations

Investigated drugs:

Thrombosis Prophylaxis Therapy is used to prevent blood clots in patients undergoing total hip or knee replacement surgery. This therapy aims to reduce the risk of developing venous thromboembolism (VTE), which includes conditions like deep vein thrombosis and pulmonary embolism. The trial is investigating whether a personalized approach to thrombosis prevention is as effective as the standard method, which is typically the same for all patients. The therapy may involve medications that help prevent blood clots by thinning the blood or other methods to reduce clotting risk.

Venous thromboembolism – This condition involves the formation of blood clots in the veins, which can lead to complications if the clots travel to other parts of the body. It typically begins with a clot forming in a deep vein, often in the legs, known as deep vein thrombosis. If the clot dislodges, it can travel to the lungs, causing a pulmonary embolism, which can affect breathing and circulation. Symptoms may include swelling, pain, and redness in the affected area, as well as shortness of breath and chest pain if the lungs are involved. The risk of developing venous thromboembolism can increase after surgery, particularly procedures involving the legs or hips. Prevention strategies often focus on reducing the risk of clot formation during and after surgery.

Trial ID:

2023-510186-98-00

NCT ID:

NCT06581965

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?